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Background: Vestibular schwannomas are slow growing, benign tumors. There are three
possible management options: surgery, radiation treatment or active surveillance. The aim
of this study was to assess the general outcome and risk of tumor recurrence.
Materials and methods: The study included 220 consecutive patients (134 women, 86 men; the
age ranged from 18 to 74) operated with the retrosigmoid transmeatal approach. The largest
extrameatal diameter of the tumor ranged from 8 to 72 mm (mean 30 mm). According to the
Samii grading scale, the tumors were classiﬁed as follows: T2–12 (6%), T3–51 (23%) and T4–
157 (71%). Gross total resection was performed in 217 patients and neartotal in 3.
Results: Two hundred and eighteen (99.1%) patients were discharged home in a satisfactory
neurological condition (GR or MD in GOS). One (0.5%) patient died due to brainstem infarc-
tion. One (0.5%) patient had unchanged severe cerebellar syndrome in comparison to the
preoperative period (SD in GOS). In long-term follow-up, one patient went blind within a few
months after surgery. Including the results of further neurosurgical procedures for CSF leak,
shunt implantation, tumor regrowth and facial nerve reanimation, 98.6% of the patients
were fully independent but with different neurological deﬁcits. Tumor recurrence was
observed in 5 (2.3%) patients during the follow-up period (mean term: 6.4 years). The average
time to recurrence diagnosis was 8.8 years. All those patients were operated on again
without any adjuvant therapy and there was no further re-growth at mean follow-up of
5.2 years.
Conclusions: Complete removal of VS is usually curative and poses very low risks of severe
disability (if audio-facial sequels are not included), mortality and long-term recurrence. For
recurrent tumors, carefully tailored revision surgery without irradiation offers a high
efﬁcacy with low risk of complications.
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Almost 100 years has passed since the publication of a
monograph by Harvey Cushing [1] and vestibular schwan-
noma (VS) is still a subject of interest in many medical
specialties. Currently, the number of publications on this topic
exceeds 250 per annum. Otolaryngology, neurosurgery, radio-
surgery and basic sciences collaborate and compete with each
other leading to a sharp increase of our knowledge about the
natural course of the disease and has improved the treatment
outcomes in recent decades.
Vestibular schwannomas are benign tumors, which are
detected more frequently between the fourth and sixth decade
of life. Currently, there are three possible management
options: surgery, radiation treatment or active surveillance.
A trend toward less radical VS surgery is seen again now,
which can be justiﬁed by the benign and slow growing nature
of the tumor, as well as by the reduction of the risk of facial
(CNVII) and auditory nerve dysfunction [2,3]. In these cohorts,
nerve function preservation is exquisite, but only extended
follow-up of 10–20 years can conﬁrm the rationale of this
approach. A literature review on the effectiveness of incom-
plete resections showed that the risk of VS recurrence is
proportional to the size of the tumor remnant [2]. Similarly,
observation and radiosurgery offer high chances of excellent
function preservation during the ﬁrst years after diagnosis, but
do not eradicate the tumor and imply a number of potential
problems in the future.
On the other hand, in centers of excellence the results of
total VS removal via the retrosigmoid approach (RSA) are
nowadays comparable. Excellent functional outcome, includ-
ing hearing preservation with near-zero recurrence and
mortality rates can be achieved after complete excision of
small VS [4–6]. For medium-to-giant VS, the RSA offers also
good facial nerve function (House–Brackmann (HB) grades I–II),
low morbidity and mortality rates [5–9]. A recent meta-
analysis on large (>3.0 cm) VS surgery via the RSA demon-
strated that good postoperative facial nerve function and
mortality rates were 63% and 0.9%, respectively, while the
gross total resection (GTR) was achieved in 79% [9].
The principles of vestibular schwannoma treatment in our
Department are based on the ideas put forward by Samii [10].
This means that the main goal of the treatment is to assure a
permanent cure by complete tumor resection, as most patients
are middle-aged and still have a long life expectancy. At the
same time, however, attempts are made to preserve facial and
auditory nerve function with the use of continuous
electrophysiological monitoring.
The average size of diagnosed VS in developed countries
decreased from 30 mm to 10 mm during the last 30 years [11].
Thanks to earlier detection and advances in surgery, including
methods of intraoperative neurophysiological monitoring, the
operative safety of VS surgery greatly improved. Function
preservation, especially of the facial and auditory nerves, are
currently in the spotlight. The overall treatment results or
post-operative complications are currently published more
rarely than previously. However, it should be kept in mind that
VS surgery takes place in the immediate vicinity of vital
structures and the procedure ‘‘ex deﬁnitione’’ is fraught with therisk of serious complications. Therefore, the objectives of this
study were: (1) analysis of the overall early and late results
after vestibular schwannoma surgery, (2) assessment of the
tumor recurrence rate.
2. Materials and methods
This series of papers is devoted to the results of surgery for
sporadic vestibular schwannoma over a period of 22 years.
Perioperative management, surgical equipment and tech-
nique were changing during the analyzed period. On the one
hand, this makes it difﬁcult to analyze the general outcome,
but, on the other hand, it creates an opportunity to depict the
gradual progress in the treatment results. Consecutive papers
in this series of papers will present different aspects of
vestibular schwannoma treatment results, complications, and
preservation of facial and auditory nerve function.
2.1. Patients
This retrospective analysis includes 220 consecutive patients
operated on for sporadic VS in the years from 1990 to 2011.
Patients with neuroﬁbromatosis type II were not enrolled in
the study. Two hundred and thirteen patients were not treated
previously for VS and 7 patients were previously ineffectively
treated in other centers. This subgroup includes 5 patients
after subtotal resections, 1 patient after stereotactic radiosur-
gery and 1 patient after prior surgery and radiosurgery. There
were 134 women and 86 men, ranging in age from 18 to 74
years old (mean – 47 y.o., median – 48 y.o.). Preoperative testing
included MR imaging with contrast medium, bone window CT
of petrous pyramids, Auditory Brainstem Response, Pure Tone
Average, Word Recognition Score, and Electromyography of
the facial nerve.
2.2. Symptoms
The symptomatology of VS in the study group is shown in
Table 1. Unilateral or asymmetric hearing loss was found in
97.8% of patients at admission.
One patient with tumor progression after two prior subtotal
resections in other centers was admitted in a fairly serious
condition. He was unable to walk and presented with
psychomotor slowing and severe cerebellar syndrome. Anoth-
er patient with tumor progression, referred from another
center after incomplete resection, presented with sustained
right limbs paresis. The remaining 218 patients were admitted
in good general condition, without limb weaknesses. The
symptomatic period ranged from 0 to 30 years (mean – 3.6
years, median – 2 years).
2.3. Tumors
The largest extrameatal diameter of the tumor ranged from 8
to 72 mm (mean – 30.1 mm; median – 30 mm). According to
various deﬁnitions of ‘‘large VS’’, the tumor diameter exceeded
20 mm in 174 (79.1%) tumors, 25 mm in 136 (61.8%) and 30 mm
in 99 (45%). The average size of the ﬁrst 110 tumors was
32.1 mm, while the average size of the last 110 tumors was
Table 2 – Tumor stage according to Samii grading scale
[12].
Tumor stage Number %
T1 (Tumor is purely intrameatal) 0 0.0
T2 (Tumor is intra-and extra-meatal) 12 5.5
T3A (Tumor is ﬁlling the cerebellopontine
angle cistern)
23 10.5
T3B (Tumor is reaching the brain stem) 28 12.7
T4A (Tumor is compressing the brain stem) 45 20.5
T4B (Tumor is severely dislocating
the brain stem and the 4th ventricle)
112 50.9
Fig. 1 – Evolution of surgical technique in the analyzed
period.
Table 1 – Signs and symptoms in the analyzed group.
Symptoms Number of patients %
Tinnitus 120 54.5
Hypoacusis 155 70.5
Deafness 60 27.3
Vertigo 46 20.9
Cerebellar symptoms 57 25.9
Trigeminal nerve symptoms 65
Including:
- Neuralgia – 6
- Neuralgia and hypoesthesia – 6
- Hypoesthesia – 32
- Paresthesia – 14
- Paresthesia and hypoesthesia – 3
- Hyperaesthesia – 2
- Lack of conjunctival and corneal reﬂexes only – 2
29.5
CNVII weakness 40 18.2
Headaches 30 13.6
Hydrocephalus 10
Including:
- Acute – 6
- Normotensive – 4
4.5
Lower cranial nerves paresis 8 3.6
Optic disk swelling 6
- With decreased vision – 4
- Without visual disturbances – 2
2.7
Other 5 2.2
Asymptomatic tumor 1 0.5
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(mean 14.6 cm3, median 9.4 cm3). According to the Samii
grading scale [12], the tumors were classiﬁed as follows: T1–0,
T2–12 (5.5%), T3–51 (23.2%) and T4–157 (71.4%, Table 2). The
structure of the tumor was solid in 185 (84.1%) cases, and cystic
in 35 (15.9%). Internal auditory canal (IAC) enlargement was
observed in 185 (84.1%) cases. Histological examination
revealed Antoni type A in 67 (30.4%), Antoni type B in 29
(13.2%) and mixed type, Antoni A + B in 124 (56.4%) patients
[13].
2.4. Surgery
Removal of the tumor was performed via the retrosigmoid
approach (RSA) with the opening of the IAC in 217 patients. In 3
patients, a translabyrinthine approach (TLA) was used. The
majority of patients (89%) were operated on by a senior
neurosurgeon (AM). Since a priority was to cure the patient
from the neoplasm, the surgery sought to complete tumor
removal macroscopically. In 217 (98.6%) cases, the tumor was
completely removed. In 3 cases, small fragments of tumorstrongly attached to the facial nerve (2) or the brain stem (1)
were left (near-total resection, NTR). The surgical technique
evolved slightly during the analyzed period (Fig. 1). During the
ﬁrst 94 procedures, the lateral park bench position was used.
Since 2005, patients were positioned supine with the head
rotated toward the healthy side (123 procedures). Sitting or
semi-sitting position was not used, because of neurosurgeon
preferences and to avoid the risks associated with this position
(mainly venous air embolism). Craniectomy was performed
during the ﬁrst 30 procedures. From 1998 to the present,
craniotomy (the last 190 procedures) with small bone ﬂap
covering the lateral part of occipital bone was used. The base of
mastoid process is then removed with a high speed drill until
the border of sigmoid sinus is visible. The approach included
wide opening the internal auditory canal with a high speed
drill and rongeurs. Over the whole analyzed period, the
microsurgical technique was employed and the priorities of
Table 3 – General early and late outcome.
Glasgow Outcome Scale [4]
Number %
GR 187 85.0
MD 31 14.1
SD 1 0.5
VS 0 0.0
D 1 0.5
Karnofsky Performance Scale [5]
Number %
100 0 0.0
90 184 83.6
80 29 13.2
70 4 1.8
60 1 0.5
0 1 0.5
N/A 1 0.5
Abbreviations: GR – good recovery; MD – moderate disability; SD –
severe disability; VS – vegetative state, D – Death, N/A – not
available.
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part while trying to preserve auditory and facial nerves. At the
end of surgery, the dura was closed watertight and the bone
ﬂap was restored (the last 190 procedures). Open mastoid air
cells were protected with wax in all patients. In addition,
since 2000, the clearance after partial mastoid process
removal was ﬁlled by autologous bone chips with ﬁbrin glue.
Intraoperative neurophysiological monitoring of the facial
nerve was routinely used since 1994. Since August 2009 (the
last 50 procedures), vasoactive perioperative prophylaxis
was routinely employed for blood supply protection of the
facial and cochlear nerves. For this purpose, nimodipine was
administered orally at a dose of 60 mg every 6 h from 3 days
before surgery to 7 days after surgery. In justiﬁed cases, i.e.,
if deep CNVII weakness (HB grades IV-VI) occurred despite
anatomical continuity preservation, intravenous infusion of
nimodipine was started at a dose of 2 mg/h (=10 ml/h) after
surgery.
2.5. Outcome evaluation
The treatment results were assessed twice: at discharge and at
a distant period, at least 6 months after surgery. The results
were appraised in three categories: (1) general early outcome
according to the Glasgow Outcome Scale (GOS) [14], (2) general
long-term results according to the Karnofsky Performance
Status Scale (KPS) [15], (3) risk of tumor recurrence.
Postoperative unilateral deafness and CNVII weakness do
not constitute a substantial limitation in normal activity
according to the GOS scale and it does not worsen the
outcome. For this reason, the auditory and facial nerve
functions were evaluated separately. Cerebellar symptoms
and lower cranial nerves palsy present at discharge were
classiﬁed as a moderate disability in GOS.
3. Results
3.1. Early outcomes
In the analyzed series, 218 (99.1%) patients left hospital in
satisfactory condition (GR or MD in the GOS scale). These
patients were independent without limb weaknesses (Table 3).
Patients in the GR group had unilateral hearing loss and/or
facial nerve weakness and/or trigeminal nerve symptoms.
Patients in the MD group additionally had cerebellar symp-
toms and/or swallowing problems. One patient had a prior
minor hemiparesis and one had impaired vision that
worsened after surgery.
One patient was moved to the neurological ward for further
rehabilitation. The patient was already bedridden, dependent,
with severe cerebellar syndrome and with weakness of the
cranial nerves from VII to XII. He was operated on for massive
tumor progression (grade T4B) after two non-radical surgeries
at another center. The postoperative course in our department
was uneventful, and the patient's condition improved slightly
(withdrawing cerebellar syndrome). At discharge, he could
walk with assistance (SD in the GOS scale).
One patient died shortly after surgery as a result of brain
stem stroke. Mortality rate in the series was 0.5%.3.2. Long-term results
The follow-up period ranged from ½ to 18 years (mean – 6.4
years, median – 6.0 years). Out of 220 patients, one patient died
in the early postoperative period and one lost to follow-up.
In long-term follow-up, including the results of further
neurosurgical procedures for CSF leak, shunt implantation,
tumor regrowth and facial nerve reanimation, all but one
patient (Karnofsky Performance Scale 70–100: 98.6%,) were
fully independent but with different neurological deﬁcits
(Table 3). One patient went blind. The blindness appeared
gradually after the patient was discharged home. Four patients
had persistent severe cerebellar symptoms (KPS 70), 29 did not
achieve satisfactory facial nerve function or had permanent
LCN palsy (KPS 80). One hundred and eighty-four patients were
qualiﬁed as KPS 90, had unilateral deafness or hearing loss and
a satisfactory function of the facial nerve (HB grades I–III),
including results of facial nerve anastomosis.
3.3. Tumor recurrence
Regrowth of the tumor was observed in 5 patients (Table 4).
There were 2 women and 3 men, ranging in age from 18 to 49
years old (mean – 38) in this group. In all 5 patients, the tumor
was completely removed macroscopically during the initial
procedure. The risk of recurrence in the analyzed series was
2.3% during mean follow-up of 6.4 years. The average time
from surgery to recurrence diagnosis was 8.8 years.
All of these patients were operated on again. In four, the
tumor was removed using a different surgical approach than
initially, i.e., TLA in three and MFA in one. One patient was
operated on via RSA again. The recurrent tumor was removed
totally (GTR) in all 5 patients.
In three patients, the recurrent tumor was located mainly
in IAC with a minor extension to the posterior fossa. Therefore,
TLA was applied during the second surgery with the aid of an
ENT team. The size of these tumors was 19 mm, 15 mm and
Table 4 – Patients with tumor recurrence.
Patient Tumor size and
grade before
treatment
Initial surgery
(approach, extent
of resection)
Time to
tumor
recurrence
Treatment
for tumor
recurrence
CNVII function in
follow-up (HB)
1 35 mm, T4B RSA, GTR 9 years TLA, GTR Grade III
2 50 mm, T4B RSA, GTR (+end-to-end
CNVII anastomosis)
6 years TLA, GTR Grade III
3 42 mm, T4B RSA, GTR 4 years TLA, GTR Grade II
4 60 mm, T4B RSA, GTR (+HFA) 10 years MFA, GTR Grade III
5 25 mm, T4A RSA, GTR (+HFA) 15 years RSA, GTR Grade III
Abbreviations: T – tumor stage according to Samii scale; CNVII – facial nerve; HFA – hypoglossal to facial nerve anastomosis; GTR – gross total
resection; RSA – retrosigmoid approach; TLA – translabyrinthine approach; MFA – middle fossa approach; HB – House–Brackmann facial nerve
function grading scale.
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during the ﬁrst surgery but ‘‘end-to-end’’ anastomosis was
performed during the same procedure. At the time of the
second operation, the ﬁnal proximal CNVII stimulation (after
the tumor removal) showed response from the facial muscles.
The anatomical continuity of the facial nerve was preserved
also in two remaining patients. The postoperative course was
complicated with transient otorrhea in one patient. The CSF
leak was stopped effectively with a sponge dressing of the
external auditory canal, without additional invasive proce-
dures.
In one patient, the tumor re-grew from the IAC into the
petrous apex, reached the petrous portion of the internal
carotid artery and destroyed the anterior surface of petrous
bone with extradural extension into the middle cranial fossa.
The size of the tumor was 33 mm and showed no signiﬁcant
progression into posterior cranial fossa. During the second
operation, MFA was used and total tumor resection was
performed. Because HFA was previously performed with
satisfactory results, there was no need to look after the CNVII
during revision surgery. The postoperative course was
uneventful.
In one case, the recurrent tumor was removed by RSA,
because it originated not from the internal auditory canal but
was located exclusively in the cerebellopontine angle. Initially,
tumor re-growth was observed and it increased from 9 mm to
14 mm in one year. The facial nerve was not preserved during
the ﬁrst surgery and HFA was performed shortly thereafter.
During the second surgery, the tumor was totally removed
without further complications.
In long-term follow-up, all 5 patients maintained their
quality of life and satisfactory CNVII function, which they
presented before the revision surgery. One patient had grade
II HB and 4 had grade III HB, including 3 patients after
previously performed HFA. Follow-up after second surgery
ranged from 3 to 7 years (average 5.2 years). No further
recurrence was noted.
Near total resection was performed in 3 of 220 patients. In
one case, a small tumor layer was left on the brainstem
surface, in one on the CNVII trunk in the cerebellopontine
angle and in one on the CNVII in porus acusticus
internus. Follow-up MRI, performed 2 years after surgery,
showed no recurrence or identiﬁable tumor remnant in two
patients. In the third patient, follow-up data were not
available.4. Discussion
The early treatment outcome of vestibular schwannoma in our
series can be considered to be satisfactory as the mortality rate
was only 0.5%. The postoperative condition of other patients,
admitted in good condition to the hospital, did not deteriorate
below MD level in GOS (99.5%). From the perspective of the
same Department, the mortality rate was substantially
reduced from 50.0% to 0.5% from the 60s of the twentieth
century to the present [16]. This is thanks to a number of
factors. Early detection of tumors and, therefore, treatment of
smaller and less symptomatic tumors are both essential. The
use of modern equipment during surgery, including operating
microscopes, microtools, ultrasonic aspirators and neuro-
physiological monitoring, improves the precision and safety of
the treatment. Of considerable importance, in addition to the
neurosurgeon's learning curve, is the increasing experience of
the whole team involved in the treatment of VS. In other
words, current success is the result of the combined progress
of neuroscience, anesthesiology, and neurorehabilitation.
Perioperative mortality of vestibular schwannoma surgery
is currently estimated in the literature at about 0.3–1.1% [12,17–
20]. A US population study revealed the factors that reduce the
risk of death after surgery. They were: younger age, Caucasian
race, having private insurance, and operation performed by a
surgeon who performs this kind of surgery more than twice a
year [18]. Yamakami et al., in a VS treatment outcome meta-
analysis estimated the risk of severe disability and death after
surgery at 2.9% and 0.63%, respectively [21].
In our series, at mean follow-up of 6.4 years, including the
results of any follow-up treatments (for HCP, CSF leak, tumor
re-growth, etc.), the general condition of 98.6% of patients was
satisfactory. These patients were independent, with no need
for assistance (KPS: 70–100).
In 84% of patients, the only deﬁcits were unilateral hearing
loss and/or minor CNVII paresis (HB grades II–III). On the one
hand, such a presentation of the results indicates the very high
efﬁcacy and safety of microsurgery. On the other hand, the
Karnofsky scale is not a sensitive indicator of the quality of life
after VS treatment. Currently, the function of facial and
auditory nerves are in the spotlight, which will be discussed
separately.
The risk of VS re-growth in the analyzed series was 2.3%
during the mean follow-up of 6.4 years. The risk of tumor
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estimated to be around 0.7–6.2% [21,22]. Ahmad et al. showed,
on a series of 2400 surgically treated VS, that the risk of tumor
recurrence is 0.7%, 1.8% and 0.05%, respectively for RSA, MFA
and TLA [22]. A literature review by Ansari et al. indicates that
the risk of tumor recurrence is higher after RSA than MFA (6.2%
vs. 1.1%; p = 0.045), possibly because MFA is useful only for
smaller tumors and because of better insight into the internal
auditory canal bottom [23].
In case of small recurrence detection, active observation
may be applied initially for tumor growth rate tracking. Some
prefer radiosurgical treatment of tumor recurrence [24].
Another optional strategy is a subsequent non-radical VS
excision while trying to preserve CNVII function as long as
possible. However, in the series of Freeman et al., revision
surgery is associated with a higher risk of postoperative
complications (23%), subsequent re-growth and deepening of
CNVII weakness (HB grades IV–VI: 54%), as compared to the
initial surgery [25].
Considering the treatment modality for VS recurrence, we
should take into account the quality of life (QOL) before and
after any further treatment. A patient's awareness of a
growing tumor despite prior treatment may play a major role.
Recent research by Carlson et al. suggests that VS diagnosis
itself has a greater impact on health related QOL than any
treatment modality [26]. This may mean that surgical
eradication of the tumor may positively inﬂuence a patient's
awareness of freedom from the disease. This thesis seems to
be conﬁrmed in papers on QOL in observed, irradiated and
surgical groups. While QOL remains stable during observation
and after radiosurgery, it signiﬁcantly improves in surgical
groups after treatment, especially in the composite mental
dimension [27,28]. Therefore, our general strategy for recur-
rent VS is radical surgery using tailored approaches together
with modern FN reconstruction techniques, if needed.
In our series, revision surgery is an effective and safe
treatment option. The recurrent tumor was completely
removed in all 5 patients, and no subsequent re-growth was
noted in further follow-up of 5.2 years on average. The only
complication was CSF leak, which was eliminated with non-
invasive methods in 1 patient. The facial nerve function was
maintained at the same level as before revision surgery in all 5
patients. However, the assessment of safety in this regard is
hampered by previously performed extratemporal CNVII
anastomosis in two patients.
A different approach than the ﬁrst one was applied in four
patients, because of the location of tumor recurrence in the
internal auditory canal or tumor extension into the petrous
apex. The important advantage of using a different approach is
also to avoid dissection across the postoperative scar, which is
strongly tied with cranial nerves as well as cerebellum and
brain stem surface [25].
A literature review on the effectiveness of incomplete
resections showed that the risk of VS recurrence is propor-
tional to the size of the tumor remnant [2]. This conﬁrms the
legitimacy of complete tumor removal. On the other hand, in
our study, all VS recurrences occurred after macroscopically
complete removal. The possible cause of recurrence could be
an invisible tumor remnant in the IAC bottom. The risk ofmissing this part of the tumor can be minimized by endoscopic
control of the IAC bottom at the end of procedure [29].
Bennett et al. postulate that, in patients after complete
resection of sporadic VS, there is no need for further follow-up
MRI, if an examination a year after the procedure shows no
pathological enhancement [30]. In the cited series, none of the
10 linear enhancements progressed over time but two tumor
recurrences progressed out of three nodular enhancements.
The linear contrast enhancement of the dura around the IAC is
usually transient and demonstrates an evolution of postoper-
ative scar. However, nodular enhancement suggests a tumor
remnant or recurrence [31].
The interval between initial surgery and recurrence
diagnosis was 8.8 years on average in our series. This fact
indicates the need for long-term surveillance even after GTR
[22]. Our recommendation is to perform the ﬁrst follow-up MRI
half a year after surgery for tumor remnant exclusion in the
IAC bottom. In the light of the presented results, it is
reasonable to perform follow-up imaging even 5 and 10 years
after surgery. This is also supported by two other arguments.
Firstly, most schwannomas are characterized by very slow
growth. Secondly, effectiveness should be veriﬁed in the same
way for radiotherapy, observation and surgery, therefore the
follow-up schedule should be comparable for all three
management modalities [24].
5. Conclusions
Complete removal of VS via the retrosigmoid approach is
usually curative and poses very low risks of severe disability (if
audio-facial sequelae are not included), mortality and long-
term recurrence. Thus, it should be considered as a ﬁrst-line
strategy option especially for larger tumors. For recurrent
tumors, carefully tailored revision surgery without irradiation
offers a high efﬁcacy with low risk of complications.
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